Taking a look at the chart above (from StockCharts.com) and observing the technical analysis you can clearly see the following moving averages:
– 50 day moving average at $.38
– 120 day moving average at $.94
– 20 day exponential moving average $.36 (key line of potential resistance)
But what you don’t see – is what this actually means in dollars and cents.
Meaning, that if Cosmos Health Inc. (COSM) trends above its first line of resistance at the $.36 range… then the next line of potential resistance may be all the way at $.94, which, if reached, would represent an approximate 161% potential move.
Furthermore, if Cosmos Health Inc. (COSM) were to climb back to $3.92 from $.36 (closing price as of 9/2/22), it would represent an approximate 988% move.
Now, I’m not saying that Cosmos Health Inc. (COSM) is going to reach those levels today, tomorrow, or next week, but you need to be aware of its potential upside from current trading levels.
You see, from a technical analysis perspective, Cosmos Health Inc. (COSM) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”
…And by definition, the “Descending Triangle Breakout Strategy,” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (31)
This strategy uses a very simple combination of trading volumes and asserting the trend, which can be used to capture short term vertical moves.(31)
The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (31)
Massive Shift To Preventive Healthcare Could Propel The Global Nutraceuticals Market To $1 Trillion By 2030. (17)
One company that could be extremely well positioned for this unprecedented opportunity is Cosmos Health Inc. (NASDAQ: COSM)…(18)
RECENT NEWS
MANAGMENT
Mr. Grigorios Siokas has over 15 years’ experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly-owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark.
Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over € 78 million); Thrakis Pharmaceuticals, (annual sales of over € 20 million); Thessalias Pharmaceuticals, (annual sales of over € 18 million); and ZED Pharma SA, (annual sales of over € 35 million).
During the 1990s, Mr. Siokas founded and operated a marble wholesale import – export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers.
Mr. Grigorios Siokas has Bachelor’s Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master’s in management and finance from the University of Stuttgart and the University of Tuebigen, Germany and has served in the Greek Army.
Dimitrios Goulielmos joined us as CEO and Director on September 27, 2013. Since January 1991, he has been the principal attorney at the law firm of Goulielmos D. & Partners. He contributes to the Board the benefits of his legal, academic, and business background.
Mr. Goulielmos is a fourth generation attorney. He received his law degree with Excellency from the Aristotle University of Thessaloniki in 1988. He did post graduate studies for International transactions and Company law at Paris, France and at the LSE of London, England.
In 2004 he was elected Vice-president of EUROPECHE, the organization that was established by the European Committee for the consultation and proposal of solutions in the sector of Community Fishery.
The same year he was also elected as National representative of Hellas in the MEDISAMAK, the organization responsible for all Mediterranean countries, in the sector of Fishery.
In year 2007 he was re-elected as Vice-president of EUROPECHE. He is a member of the social dialogue group of ACFA, of EU on labor affairs.
He is an honorary lifetime member of International Who’s Who Historical Society.
Mr. Goulielmos has extensive experience in law, international deals, mergers, acquisitions, negotiations, international application of licenses, and real estate management which he will contribute to the Board.
Mr. Demetrios G. Demetriades was elected as Secretary and Director of the Company.
Since January 2003, Mr. Demetriades, age 48, has been Director of Highlander Spring Trading Ltd, a trading company.
From November 2000 to December 2002 he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange.
From January 1995 to November 2000 he was Supervising Officer of Laiki Factors Ltd, a financing company.
As a member of the board, Mr. Demetriades contributes the benefits of his trading, executive leadership and management experience.
On November 18, 2016, John J. Hoidas was appointed as a member of the Board of Directors of Cosmos Holdings. Mr. Hoidas is a registered broker dealer. John J. Hoidas began working on the floor of the CME in 1989 as a runner and by 1995 started trading the S&P 500 and GSCI Index Futures for 9 years. In 2004, he transitioned to wealth management at American Express Financial Advisors which spun off to Ameriprise. In 2010, he joined Kingsbury Capital & began raising money for late-stage pre-IPO companies such as Organovo (ONVO), Invivo Therapeutics (NVIV) and Matinas BioPharma (MTNB) to name a few. John previously served as a Senior Vice President at Uhlmann Price. At Uhlmann Price Securities, he has raised capital for startups such as Video Gaming Co; Gazillion, Inc., Liquidspace, and Revel Systems.
Dr. Aslidis was appointed as a member of the Board of Directors of Cosmos Holdings on April 28, 2022. Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018. He is Chief Financial Officer, Treasurer and a member of the Board of Directors of Euroseas (Nasdaq: ESEA) since September 2005. Furthermore, Dr. Aslidis has been a director of Vianair Inc., a private company active in airspace design and airport operations analysis since 2017. Prior to joining Euroseas, Dr. Aslidis was a partner at Marsoft Inc., an international consulting firm focusing on investment and risk management in the maritime industry. Dr. Aslidis has more than 30 years of experience in the maritime industry. He also served as consultant to the Boards of Directors of public and private companies advising on strategy development, asset selection and investment timing. Dr. Aslidis holds a Ph.D. in Ocean Systems Management (1989) from the Massachusetts Institute of Technology, M.S. in Operations Research (1987) and M.S. in Ocean Systems Management (1984), also from the Massachusetts Institute of Technology, and a Diploma in Naval Architecture and Marine Engineering from the National Technical University of Athens (1983).